tbuckley/cabot-search huggingface dataset:
Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years
Authors: Jianwei Zhang, Pan Chi, Lishuo Shi, Long Cui, Jinbo Gao, Wanglin Li, Hongbo Wei, Longqing Cheng, Zonghai Huang, Guangfu Cai, Ren Zhao, Zhongcheng Huang, Hongfeng Zhou, Yisheng Wei, Hao Zhang, Jian Zheng, Yan Huang, Yue Cai, Zhiyang Zhou, Liang Kang, Meijin Huang, Xiaojian Wu, Junsheng Peng, Donglin Ren, Ping Lan, Jianping Wang, Yanhong Deng
Journal: Journal of Clinical Oncology (2024)

We present 10-year results of the phase Ⅲ FOWARC trial, which evaluated the efficacy of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with or without radiation compared with fluorouracil with radiation in patients with locally advanced rectal cancer. A total of 495 patients age 18-75 years with stage Ⅱ-Ⅲ rectal cancer were randomly assigned to three treatment arms: fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, or mFOLFOX6 alone, followed by surgery and adjuvant chemotherapy. With a median follow-up of 10 years, the 10-year disease-free survival (DFS) rates were 52.5%, 62.6%, and 60.5%, respectively ( P = .56). The 10-year locoregional recurrence (LR) rates were 10.8%, 8.0%, and 9.6% ( P = .57), and the 10-year overall survival (OS) rates were 65.9%, 72.3%, and 73.4% ( P = .90). Subgroup analysis identified ypTNM stage as a significant prognostic factor for DFS, LR, and OS ( P &lt; .0001, P &lt; .006, P &lt; .0001, respectively). Patients achieving pathologic complete response had 10-year DFS, LR, and OS rates of 84.3%, 3.0%, and 92.4%, respectively. No significant difference was observed in long-term survival outcome between mFOLFOX6 with and without radiation and fluorouracil plus radiation. These results demonstrate that neoadjuvant mFOLFOX6 chemotherapy can be considered as a therapeutic option in LARC.
High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial
Authors: William J. Aronson, Tristan Grogan, Pei Liang, Patricia Jardack, Amana R. Liddell, Claudia Perez, David Elashoff, Jonathan Said, Pinchas Cohen, Leonard S. Marks, Susanne M. Henning
Journal: Journal of Clinical Oncology (2024)

PURPOSE Men on active surveillance (AS) for prostate cancer are extremely interested in dietary changes or supplements to prevent progression of their disease. We sought to determine whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules (D + FO) decreases proliferation (Ki-67) in prostate biopsies in men with prostate cancer on AS over a 1-year time period. METHODS In this phase II, prospective randomized trial, men (N = 100) with grade group 1 or 2 prostate cancer who elected AS were randomly assigned to the D + FO or a control group. Same-site prostate biopsies were obtained at baseline and 1 year. The primary end point was the change in Ki-67 index from baseline to 1 year from same-site biopsies compared between the groups. RESULTS The Ki-67 index decreased in the D + FO group by approximately 15% from baseline to 1 year (1.34% at baseline, 1.14% at 1 year) and increased in the control group by approximately 24% from baseline to 1 year (1.23% at baseline, 1.52% at 1 year), resulting in a statistically significant difference in the change of Ki-67 index between the groups (95% CI, 2% to 52%, P = .043). There was no significant difference in the secondary outcomes grade group, tumor length, Decipher genomic score, or prostate-specific antigen between the two groups. Four patients in the D + FO group were withdrawn from the trial because of adverse events related to the FO. CONCLUSION A high omega-3, low omega-6 diet with FO for 1 year resulted in a significant reduction in Ki-67 index, a biomarker for prostate cancer progression, metastasis, and death. These findings support future phase III trials incorporating this intervention in men on AS.
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
Authors: Hussein A. Tawbi, F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Juliana Janoski De Menezes, Stéphane Dalle, Ana Maria Arance, Jean-Jacques Grob, Barbara Ratto, Saima Rodriguez, Antonella Mazzei, Sonia Dolfi, Georgina V. Long
Journal: Journal of Clinical Oncology (2024)

Nivolumab plus relatlimab demonstrated a statistically significant improvement in progression-free survival (PFS), along with a clinically meaningful, but not statistically significant improvement in overall survival (OS) and a numerically higher objective response rate (ORR) compared with nivolumab in the RELATIVITY-047 trial (ClinicalTrials.gov identifier: NCT03470922 ). We report updated descriptive efficacy and safety results from RELATIVITY-047 with a median follow-up of 33.8 months. Median PFS was 10.2 months (95% CI, 6.5 to 15.4) with nivolumab plus relatlimab and 4.6 months (95% CI, 3.5 to 6.5) with nivolumab (hazard ratio [HR], 0.79 [95% CI, 0.66 to 0.95]); median OS was 51.0 months (95% CI, 34.0 to not reached) and 34.1 (95% CI, 25.2 to 44.7) months, respectively (HR, 0.80 [95% CI, 0.66 to 0.99]). ORR was 43.7% (95% CI, 38.4 to 49.0) with nivolumab plus relatlimab and 33.7% (95% CI, 28.8 to 38.9) with nivolumab. Efficacy across the majority of prespecified subgroups favored the combination. No new or unexpected safety signals were identified. Overall, at 3-year follow-up, the benefit observed with nivolumab plus relatlimab compared with nivolumab in patients with advanced melanoma was sustained, with the OS HR 95% CI upper bound now &lt;1. This benefit is accompanied by a safety profile consistent with previous reports.
Sex chromosome turnovers and stability in snakes
Authors: Tomáš Pšenička, Barbora Augstenová, Daniel Frynta, Panagiotis Kornilios, Lukáš Kratochvíl, Michail Rovatsos
Journal: Molecular Biology and Evolution (2024)

Abstract For a long time, snakes were presented as a textbook example of a group with gradual differentiation of homologous ZZ/ZW sex chromosomes. However, recent advances revealed that the ZZ/ZW sex chromosomes characterize only caenophidian snakes and certain species of boas and pythons have nonhomologous XX/XY sex chromosomes. We used genome coverage analysis in four non-caenophidian species to identify their sex chromosomes, and we examined the homology of sex chromosomes across phylogenetically informative snake lineages. We identified sex chromosomes for the first time in 13 species of non-caenophidian snakes, providing much deeper insights into the evolutionary history of snake sex chromosomes. The evolution of sex chromosomes in snakes is more complex than previously thought. Snakes may have had ancestral XX/XY sex chromosomes, which are still present in a blind snake and some boas, and there were several transitions to derived XX/XY sex chromosomes with different gene content and two or even three transitions to ZZ/ZW sex chromosomes. However, we discuss more alternative scenarios. In any case, we document that (1) some genomic regions were likely repeatedly co-opted as sex chromosomes in phylogenetically distant lineages, even with opposite types of heterogamety; (2) snake lineages differ greatly in the rate of differentiation of sex chromosomes; (3) snakes likely originally possessed sex chromosomes prone to turnovers. The sex chromosomes became evolutionarily highly stable once their differentiation progressed in the megadiverse caenophidian snakes. Snakes thus provide an ideal system for studying the evolutionary factors that drive unequal rates of differentiation, turnovers and stability of sex chromosomes.
Author Correction: Activation of GPR81 by lactate drives tumour-induced cachexia
Authors: Xidan Liu, Shijin Li, Qionghua Cui, Bujing Guo, Wanqiu Ding, Jie Liu, Li Quan, Xiaochuan Li, Peng Xie, Li Jin, Ye Sheng, Wenxin Chen, Kai Wang, Fanxin Zeng, Yifu Qiu, Changlu Liu, Yan Zhang, Fengxiang Lv, Xinli Hu, Rui-Ping Xiao
Journal: Nature Metabolism (2024)
Association between childhood adversity and use of the health, social, and justice systems in Denmark (DANLIFE): a nationwide cohort study
Authors: Bertina Kreshpaj, Leonie K Elsenburg, Signe Hald Andersen, Tjeerd Rudmer De Vries, Karsten Thielen, Naja Hulvej Rod
Journal: The Lancet Public Health (2024)

Childhood adversities can negatively affect health and social outcomes. We aimed to assess the association between adversity in childhood and use of public services in early adulthood across three systems: health, social welfare, and justice.
Bioinspired conductive oriented nanofiber felt with efficient ROS clearance and anti-inflammation for inducing M2 macrophage polarization and accelerating spinal cord injury repair
Authors: Qingxia Zhang, Jiahe Zheng, Linlong Li, Jui-Ming Yeh, Xianrui Xie, Yuqing Zhao, Chengbo Li, Guige Hou, Huanhuan Yan
Journal: Bioactive Materials (2024)
Characterization of peripapillary hyperreflective ovoid mass-like structures (PHOMS) in a broad spectrum of neurological disorders
Authors: Jonathan A Gernert, Tara Christmann, Elisabeth Kaufmann, Luisa Delazer, Isabel Kirsch, Johannes Levin, Sonja Schönecker, Urban M Fietzek, Peter Zu Eulenburg, Theresa Velten, Marina Gripshi, Klaus G Parhofer, Esther M Maier, Tania Kümpfel, Amelie S Lotz-Havla, Joachim Havla
Journal: Ophthalmology (2024)
Non-alcohol-related cirrhosis leads to higher 6-week mortality after acute variceal bleeding than alcohol-related cirrhosis
Authors: Yu Jun Wong, Adam Buckholz, Alyssa Sim, Margaret Teng, Rochelle Wong, Michael P Curry, Marianne Anastasia DE Roza, Gyorgy Baffy, Xuhui Teoh, Eric Chak, Tarun Rustagi, Jason Chang, Guan Wee Wong, Puneeta Tandon, Guadalupe Garcia-Tsao, Juan G Abraldes, Arpan Mohanty, Brett Fortune
Journal: Clinical Gastroenterology and Hepatology (2024)
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Application and Interpretation of the Residual Tumor (R) Classification for Lung Cancer. Results from an International Survey among Pathologists and Thoracic Surgeons
Authors: Hans Hoffmann, Andrew G Nicholson, Frank C Detterbeck, Ming S Tsao, Marcin Ostrowski, Ramón Rami-Porta, Alain Borczuk, Mirella Marino, William D Travis, Paul E Van Schil, John Edwards
Journal: Journal of Thoracic Oncology (2024)
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease
Authors: Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao
Journal: Journal of Hepatology (2024)
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families
Authors: Julie Jemutai, Louise Downs, Motswedi Anderson, Chari Cohen, Janet Seeley, Binta Sultan, Joy Ko, Stuart Flanagan, Collins Iwuji, Rachel Halford, Oriel Fernandes, Peter Vickerman, Asgeir Johannessen, Philippa C Matthews
Journal: The Lancet. Gastroenterology & hepatology (2024)
Adaptive HIV pre-exposure prophylaxis adherence interventions for young women in Johannesburg, South Africa: a sequential multiple-assignment randomised trial
Authors: Jennifer Velloza, Nicole Poovan, Allison Meisner, Nontokozo Ndlovu, Nomhle Ndimande-Khoza, Cole Grabow, Phumzile Zwane, Samukelo Mbele, Mapaseka Molefe, Deborah Donnell, Jared M Baeten, Sybil Hosek, Connie Celum, Sinead Delany-Moretlwe
Journal: The Lancet HIV (2024)
Vanadium Single-Atoms Coordinated Artificial Peroxidases as Biocatalyst-Linked Immunosorbent Assay for Highly-Sensitive Carcinoembryonic Antigen Immunoassay
Authors: Minjia Yuan, Rui Yan, Zhenyang Zhao, Qinlong Wen, Xiaodong Xie, Mohsen Adeli, Shuang Li, Chong Cheng
Journal: Biomaterials (2024)
Acceptability of an organ inventory for cancer screening across gender identity and intersex status
Authors: Heidi Moseson, Sachiko Ragosta, Anu Manchikanti Gómez, Jae Corman, Jay Zussman, Bori Lesser-Lee, Sydney Reese, India Rose Carter-Bolick, Juno Obedin-Maliver
Journal: JNCI Journal of the National Cancer Institute (2024)

Abstract Objectives To evaluate the acceptability and performance of an organ inventory as an alternative to asking about gender and/or sex assigned at birth in cancer screening. Methods We fielded an online, self-administered survey to a convenience sample of English- or Spanish-speaking transgender and gender-diverse (TGD), intersex, and cisgender people (&amp;gt;/=15 years) in the US. The survey contained an organ inventory developed with community input and questions regarding acceptability. The primary outcome was organ inventory acceptability by the four-item Acceptability of Intervention Measure (AIM). Additional outcomes included inter-method screening agreement between the organ inventory, gender, and sex assigned at birth. Results In 2022, 333 eligible individuals completed the survey; 44.4% cisgender, 34.2% TGD, and 14.1% intersex. Overall, participants rated the organ inventory as acceptable (median AIM score = 18/20, IQR: 16-20). Most (73%) found it easy to understand, and comfortable to complete (65%). Cancer screening eligibility varied based on the method used; relying solely on gender or sex data would have missed some eligible participants that the organ inventory identified. Conclusions Using an organ inventory as an alternative to gender or sex-based screening questions was acceptable, and has implications for addressing cancer screening disparities.
Artificial intelligence for a rare disease
Authors: Yuichi Mori
Journal: Endoscopy (2024)

Imagine performing a gastroscopy on a 50-year-old lady with epigastric pain, guided by an advanced artificial intelligence (AI) system that suggests autoimmune gastritis and encourages a biopsy. With the AI tool offering an excellent diagnostic yield of 90% sensitivity and 90% specificity, would you follow its recommendation?
Antiviral and immunomodulatory effects of ouabain against Congenital Zika Syndrome model
Authors: Deyse Cristina Madruga Carvalho, Tiffany Dunn, Rafael Kroon Campos, Jessica A Tierney, Florence Onyoni, Luiz Henrique Agra Cavalcante-Silva, Lindomar José Pena, Sandra Rodrigues-Mascarenhas, Ping Wu, Scott C Weaver
Journal: Molecular Therapy (2024)
Advances in biomaterial-based tissue engineering for peripheral nerve injury repair
Authors: Xinlei Yao, Tong Xue, Bingqian Chen, Xinyang Zhou, Yanan Ji, Zihui Gao, Boya Liu, Jiawen Yang, Yuntian Shen, Hualin Sun, Xiaosong Gu, Bin Dai
Journal: Bioactive Materials (2024)
Neighborhood social determinants of health are associated with metabolic dysfunction-associated steatotic liver disease outcomes
Authors: Claire S Faulkner, Majd B Aboona, Likith Surendra, Pooja Rangan, Cheng Han Ng, Daniel Q Huang, Mark Muthiah, Donghee Kim, Michael B Fallon, Mazen Noureddin, Vincent L Chen, Ani Kardashian, Karn Wijarnpreecha
Journal: Clinical Gastroenterology and Hepatology (2024)
“3D channel maze” to control drug release from multiple unit tablets
Authors: Huipeng Xu, Liu Zhang, Longwei Fang, Dunwei He, Peter York, Lixin Sun, Jianzhao Niu, Qian Liu, Mingdi Xu, Yanling Xue, Guanyun Peng, Tiaoqiao Xiao, Zhuoma Basang, Xianzhen Yin, Li Wu, Jiwen Zhang
Journal: Journal of Controlled Release (2024)
Early warning scores: a system designed in a hospital ward is unlikely to work in general practice
Authors: Damian T Roland
Journal: BMJ (2024)

paediatric emergency medicine consultantAll data on the application of safety systems is useful, and Clark and colleagues' work on the National Paediatric Early Warning System (PEWS) cited by Salisbury is an important addition to the literature. 1 2 It's important to highlight, however, that the wholescale lifting of a system designed in a hospital ward straight into the community was never going to be successful.Time and time again the system safety literature has told us interventions are context, and sometimes patient, specific.It was never the intention of the PEWS programme board to do this.As part of the SPOT (System Wide Paediatric Observation Tracking) programme we had always intended to create a standardised approach in inpatients, then start aligning this with processes in emergency departments (this work will be released in 2025), and then move towards pre-hospital and primary care.The hope is to have a tool that is additive to the clinical gestalt of the primary care clinician (which Salisbury points out is probably the most important part of the diagnostic process) and, rather than create a new score, we have something that aids communication with other healthcare professionals using a common and standardised language.Clark and colleagues' paper supports what we already knew.A score designed to pick up a deteriorating patient on the ward is not going to pick up a potentially unwell patient in a general practice with anywhere near the specificity to be credible in practice.The National PEWS programme board (which does include GP representation) fully supports Salisbury's comments on the subtleties of illness recognition in primary care.Whatever "system" is rolled out to align with the inpatient charts will be very cognisant of this.
Single-cell data-driven design of armed oncolytic virus and combination therapy to activate a cooperative innate-adaptive immunity against cancer
Authors: Jiliang Zhao, Han Wang, Chunlei Wang, Fan Li, Jingru Chen, Feilong Zhou, Yiping Zhu, Jinhua Chen, Jinming Liu, Hao Zheng, Nanxin Gong, Yazhuo Du, Yufan Zhang, Li Deng, Yuyao Du, Yanqin Liu, Yuanke Li, Na Li, Hongru Zhang, Dan Ding, Shouzhi Yu, Cuizhu Zhang, Yingbin Yan, Wei Wang, Youjia Cao, Yuntao Zhang, Hongkai Zhang
Journal: Molecular Therapy (2024)

Oncolytic viruses have been considered promising cancer immunotherapies. However, oncovirotherapy agents impart durable responses in only a subset of cancer patients. Thus, exploring the cellular and molecular mechanisms underlying the heterogeneous responses in patients can provide guidance to develop more effective oncolytic virus therapies. Single-cell RNA sequencing (scRNA-seq) analysis of tumors responsive and non-responsive to oncovirotherapy revealed signatures of the tumor immune microenvironment associated with immune response. Thus, we designed and constructed an armed oncolytic virus OV-5A that expressed five genes with non-redundant functions. OV-5A treatment exhibits robust immune response against various tumors in multiple mouse models, peripheral blood mononuclear cell (PBMC)-patient derived xenograft (PDX) model, organoid-immune cell co-culture systems and patient tissue sections by activating a cooperative innate-adaptive immune response against tumor cells. scRNA-seq analysis of complete responder and partial responder to OV-5A treatment guided the design of combination therapy of OV-5A. This data-driven approach paves a innovative way to rationalize the design of oncolytic virus and multi-agent combination therapies.
Clinical, histological and safety outcomes with long-term maintenance therapies for eosinophilic esophagitis: A systematic review and meta-analysis
Authors: Alberto Barchi, Luca Massimino, Francesco Vito Mandarino, Mona-Rita Yacoub, Luca Albarello, Edoardo Vincenzo Savarino, Federica Ungaro, Silvio Danese, Sandro Passaretti, Albert J Bredenoord, Edoardo Vespa
Journal: Clinical Gastroenterology and Hepatology (2024)
Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in Inflammatory Bowel Disease: A Systematic Review and Network Meta-Analysis
Authors: Vasiliki Sinopoulou, Gaurav B Nigam, Morris Gordon, Meghana Ganeshan, Mitchell Rudo Tokonyai, Sunil Dolwani, Marietta Iacucci, Matt Rutter, Venkat Subramanian, Ana Wilson, James E East
Journal: Clinical Gastroenterology and Hepatology (2024)
Acute Kidney Injury in Patients with Cirrhosis and Chronic Kidney Disease: Results from the HRS-HARMONY Consortium
Authors: Shelsea A St Hillien, Jevon E Robinson, Tianqi Ouyang, Kavish R Patidar, Justin M Belcher, Giuseppe Cullaro, Kevin R Regner, Raymond T Chung, Nneka Ufere, Juan Carlos Q Velez, Javier A Neyra, Sumeet K Asrani, Hani Wadei, J Pedro Teixeira, Danielle L Saly, Josh Levitsky, Eric Orman, Deirdre Sawinski, Leigh Anne Dageforde, Andrew S Allegretti
Journal: Clinical Gastroenterology and Hepatology (2024)
Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-Based Cohort Study 1997-2020
Authors: Henrik Albaek Jacobsen, Anastasia Karachalia-Sandri, Anthony C Ebert, Kristine H Allin, Ashwin N Ananthakrishnan, Manasi Agrawal, Ryan C Ungaro, Jean-Frederic Colombel, Lone Larsen, Tine Jess
Journal: Clinical Gastroenterology and Hepatology (2024)
Mortality in adult patients with chronic spontaneous urticaria: A real world cohort study
Authors: Pavel Kolkhir, Katja Bieber, Tomasz Hawro, Khalaf Kridin, Marlene A Ludwig, Henning Olbrich, Martin Metz, Artem Vorobyev, Ralf J Ludwig, Marcus Maurer
Journal: Journal of Allergy and Clinical Immunology (2024)
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent
Authors: Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna, Isla M. Johnson, Maymona Abdelmagid, Aref Al‐Kali, Hassan B. Alkhateeb, Kebede H. Begna, Michelle Elliott, Abhishek Mangaonkar, Aasiya Matin, Antoine N. Saliba, Mehrdad Hefazi Torghabeh, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Arana Yi, Samuel Yates, Abigail Sneider, Emily Dworkin, Anand A. Patel, Alexandre Bazinet, Jayastu Senapati, Alex Bataller, Courtney DiNardo, Tapan Kadia, Ayalew Tefferi
Journal: American Journal of Hematology (2024)

Patients with newly diagnosed acute myeloid leukemia (ND-AML) derive variable survival benefit from venetoclax + hypomethylating agent (Ven-HMA) therapy. The primary objective in the current study was to develop genetic risk models that are predictive of survival and are applicable at the time of diagnosis and after establishing treatment response. Among 400 ND-AML patients treated with Ven-HMA at the Mayo Clinic, 247 (62%) achieved complete remission with (CR) or without (CRi) count recovery. Multivariable analysis-derived hazard ratios (HR), including 1.8 for European LeukemiaNet (ELN) adverse karyotype, 4.7 for KMT2Ar, 1.7 for TP53
The Low-Cost, Battery-Powered AI-Enabled Ultrasound Device That Could Improve Global Obstetric Care
Authors: Roy Perlis, Kate Schweitzer
Journal: JAMA (2024)

This Medical News article is an interview with Jeffrey S. A. Stringer, MD, whose commitment to global health equity has led to advancements in artificial intelligence-enabled tools that can accurately estimate gestational age during pregnancy without trained sonographers.
The Importance of Parent and Clinician Stakeholder Input—Guiding the Guidelines on Pediatric Hypertension
Authors: Carissa M. Baker-Smith
Journal: JAMA Network Open (2024)

Abbas H. Zaidi, MD, MS; Erica Sood, PhD; Sarah De Ferranti, MD, MPH; Samuel Gidding, MD; Varsha Zadokar, MBBS; Jonathan Miller, MD; Anne Kazak, PhD
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
Authors: B Martínez-Castedo, D G Camblor, J Martín-Arana, J A Carbonell-Asins, B García-Micó, V Gambardella, M Huerta, S Roselló, D Roda, F Gimeno-Valiente, A Cervantes, N Tarazona
Journal: Annals of Oncology (2024)
Trial Shows It’s Safe to Get COVID-19, Flu Vaccines at the Same Time
Authors: Samantha Anderer
Journal: JAMA (2024)

Emmanuel B. Walter, MD, MPH; Elizabeth P. Schlaudecker, MD, MPH; Kawsar R. Talaat, MD; Wes Rountree, MPH; Karen R. Broder, MD; Jonathan Duffy, MD, MPH; Lisa A. Grohskopf, MD, MPH; Marek S. Poniewierski, MD, MS, MS; Rachel L. Spreng, PhD; Mary A. Staat, MD, MPH; Rediet Tekalign, MD, MPH; Oidda Museru, MSN, MPH; Anju Goel, MD, MPH; Grace N. Davis, MS; Kenneth E. Schmader, MD